Moffitt Cancer Center Teams Up with AstraZeneca for Oncology Innovation
Moffitt Cancer Center is excited to share a new strategic collaboration with AstraZeneca aimed at advancing cutting-edge cell therapies. This partnership will primarily focus on chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies. By combining Moffitt’s clinical strengths with AstraZeneca's innovative strategies, both organizations aim to pioneer advancements in cancer treatment.
Main Goals of the Collaboration
This alliance brings AstraZeneca into Moffitt's elite clinical setting, essential for fostering strong connections with physician-scientists. Together, they will work towards speeding up the research and application of new cell therapies. As treatments in this area evolve rapidly, progress is crucial as it may provide new hope for patients suffering from cancers that currently have no effective treatments available.
The Development of Cell Therapies
Since CAR T therapies were introduced in 2017, the field of cancer treatment has changed dramatically. Moffitt Cancer Center has been instrumental in the clinical trials leading to multiple FDA approvals for these groundbreaking therapies. With the rising demand for advanced oncology treatments, Moffitt is enhancing its capabilities and expanding its network of cancer centers across the country.
Advancing Cancer Care
This collaboration aims to tackle the significant hurdles faced in developing cell therapies, with a goal of making these treatments accessible to a larger number of patients both in the U.S. and around the globe. A key focus will be on advancing clinical trials that assess the effectiveness of cell therapies in treating solid tumors, while also improving clinical operations. This targeted strategy will enable quicker access to autologous cell therapies for patients in need.
Leadership Insights
Patrick Hwu, M.D., president and CEO of Moffitt, expressed his enthusiasm about the partnership: "We are thrilled to work with AstraZeneca to push the boundaries of what's achievable in cancer treatment. By merging our clinical know-how with AstraZeneca's innovative pipeline of investigational cell therapies and their global presence in oncology, we aspire to deliver potential new therapies to patients more quickly and efficiently.”
Carsten Linnemann, Head of Oncology Cell Therapy Clinical Development at AstraZeneca, mentioned, “This collaboration will enhance our relationship with Moffitt Cancer Center, allowing us to accelerate our autologous cell therapy pipeline aimed at transforming cancer treatment for patients with both hematological and solid tumors.”
About Moffitt Cancer Center
Moffitt is focused on a singular lifesaving mission: to aid in the prevention and cure of cancer. This prestigious organization is acknowledged as one of the 57 National Cancer Institute-designated Comprehensive Cancer Centers, which underlines its scientific excellence, multidisciplinary research efforts, and commitment to education and training. Moffitt is particularly distinguished by its exceptional nursing staff, recognized with Magnet status—a prestigious honor in the healthcare field. For more information regarding Moffitt's pioneering work or to get in touch, please call 1-888-MOFFITT (1-888-663-3488) or visit MOFFITT.org.
Frequently Asked Questions
What is the purpose of the collaboration between Moffitt and AstraZeneca?
The goal of the collaboration is to speed up the development and application of innovative cell therapies for cancer treatment, improving research and clinical outcomes.
How could this partnership benefit cancer patients?
By utilizing shared resources and expertise, the partnership aims to provide faster access to advanced cancer therapies, especially for those with solid tumors.
What type of cell therapies are being developed?
The collaboration primarily focuses on chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies, which are known for their potential in treating challenging cancers.
Why are cell therapies significant in oncology?
Cell therapies offer a transformative methodology in oncology, presenting new treatment options for many cancers that currently possess limited effective solutions.
How can people find out more about Moffitt Cancer Center?
People can visit MOFFITT.org or reach out to their office for additional information regarding their services, research programs, and patient care initiatives.
